cANCER

Cancer is a priority disease for LIH and research efforts cover all its facets, with Precision Oncology at the heart of our efforts. 

Our focus research areas include immuno-oncology, neuro-oncology, the tumour microenvironment, tumour metabolism and tumour genetics. Dedicated expertise is available for selected cancer types including brain cancers and haematological malignancies. In addition, LIH hosts Luxembourg’s National Cancer Registry (Registre National du Cancer, RNC), a core component of the national cancer control strategy. The RNC is a population-based cancer registry (PBCRs) and collects information from multiple sources on all new cancers diagnosed or treated in Luxembourg for public health and research purposes.

LIH also conducts research on cancer prevention and care, including risk factor identification and health data expertise, and digital biomarkers, using Patient-reported outcome measures (PROMs) and patient-reported experience measures (PREMS) to improve cancer patient outcomes (“Luxembourg to speed up the standardisation of clinical data” and Colive Voice project).

LIH investigates mechanistic processes that are fundamental for cancer initiation, progression and resistance to treatment. These include reciprocal crosstalk between tumour and non-neoplastic cells, cancer genetics and epigenetics, resistance to treatment, cancer metabolism and processes of invasion and metastasis.

The goal is to understand the biology of the disease in order to advance novel concepts from the prediction of response to therapy, the identification of novel targets for treatment to the development of innovative treatment approaches. A particular focus lies in developing and improving immunotherapies.

In parallel LIH has built up a strong expertise in selected cancer types, including brain cancer and blood malignancies.

For brain cancer, LIH focuses on malignant gliomas, including Glioblastoma (GBM), and brain metastases, leveraging on an in-house collection of more than 500 cross-sectional patient-derived tumour samples (PRECISION_PDX cohort). An extensive cohort of ex vivo and in vivo patient avatars has been generated and made publicly available. LIH also has a strong expertise in neuropathology through the PEARL chair in neuropathology leading to the creation of the Luxembourg Center of Neuropathology (LCNP).

In terms of haematological malignancies, LIH’s research activities concentrate on chronic lymphocytic leukaemia and the interaction of tumour cells with their microenvironment.

Through the Personalised Functional Profiling (PFP) project, dedicated to patients with GBM and gastro-intestinal cancers (GIC), we aim to deliver personalized treatment options based on upfront drug-response parameters determined on each patient’s tumour.

To maximise the clinical impact of LIH’s translational research and in close alliance with the National Cancer Plan (PNC), LIH has paved the way towards a National Center for Translational Cancer Research, with the aim to foster precision oncology, public health research and immunotherapies in Luxembourg.

LIH research groups

Several LIH research groups are currently working on this highly transversal priority area, integrating a broad set of in-house methodologies and capacities — ranging from ‘-omic’ approaches to patient-based models, risk factor identification, cancer epidemiology, exposure measurement and digital health expertise — thus studying the disease from different angles in a truly holistic way.

Discover the different research groups below. 

Projects & clinical trials

Department of Cancer Research
Extracellular vesicle RNA as systemic modulators of the tumor microenvironment in B cell lymphoma
Department of Cancer Research
Study of chronic lymphocytic exosomes and their impact on leukemogenesis
Department of Cancer Research
Role of AHR and HIF1α transcription factors in normal and chroniclymphocytic leukemia B lymphocytes
Department of Cancer Research
Inhibition of prohibitins and translation in chronic lymphocytic leukemi
Department of Cancer Research
Characterization of the tumor and its microenvironment in chronic lymphocytic leukemia
Department of Cancer Research
Role of regulatory T cells in the development and progression of chroniclymphocytic leukemia
Department of Cancer Research
Reprogramming of the leukemic microenvironment by small extracellular vesicles: from characterization totherapeutic application
Department of Cancer Research
Involvement of leukemic-derived extracellular vesicles in tumor microenvironment metabolic rewiring
Department of Cancer Research
Impact of Chronic Lymphocytic Leukemia-derived extracellular vesicles onthe microenvironment immune landscape
Department of Cancer Research
Immunotherapies and drug screening in improved patient-derived models: a translational approach towards personalized treatments for leukaemia
Department of Infection and Immunity
Modulation of cytokine pathways for allergy specific immunotherapy
Transversal Translational Medicine (TTM)
integrating immune strategies for Translational Research in Oncology and Neurology
Department of Infection and Immunity
Development of chemokine receptor modulators for improved cancer immunotherapy
Department of Infection and Immunity
Pre-clinical evaluation of immunoconjugates activating NK cells in cancer models
Department of Cancer Research
Biological and clinical implications of PD-L1 protein polarization at the tumor tissue and cell levels
Department of Cancer Research
Understanding the Flexibility of 1C metabolism and its role during metastatic dissemination of cancer cell
Department of Infection and Immunity
Molecular mechanisms of chronic inflammation connected to cancer development
Department of Infection and Immunity
Expression and functional characterization of the CXCR3-CXCR7heterodimer in glioblastoma
Department of Infection and Immunity
Nanobody-enabled structural and functional studies of Chemokine-CCR5 active-state complexes
Department of Infection and Immunity
Multidimensional regulation of the opioid network by ACKR3
Department of Infection and Immunity
Unraveling the role of the ACKR3/CXCR7 receptor in glioblastoma cells survival and invasion in the tumor relapse.
Department of Infection and Immunity Department of Cancer Research
Targeting chemokine receptors for improved cancer immunotherapy
Department of Infection and Immunity
Megakines – novel tools for structural insight into receptor:chemokine complexes
Department of Infection and Immunity
Megakines – novel tools for structural insight into receptor:chemokine complexes
Department of Infection and Immunity
Assessment of SARS-CoV-2neutralizing antibodies inLuxembourg through novel highlysensitive NanoLuciferase-basedhigh throughput assays
Department of Cancer Research
Actin remodeling in autophagy-mediated tumor immune escape,mechanistic aspects
Department of Cancer Research
Actin cytoskeleton remodeling in tumor immune evasion – mechanisticaspects
Department of Cancer Research
CRP2, an innovative target for metastatic breast cancer, with multiple rolesin the tumour and tumour microenvironmen
Department of Cancer Research Department of Infection and Immunity
Targeting a key promoter of multiple pro-metastatic pathways in breast cancer
Department of Cancer Research
Inhibition of Breast Cancer Metastasis by Co-targeting Two Actin Regulators
Department of Cancer Research
A LIM domain protein with multiple roles in breast cancer progression and metastas
Department of Cancer Research
Inhibition of breast cancer metastasis by targeting critical cytoskeletal components of invadopodia
Department of Cancer Research
Novel synaptic filopodium-like protrusions (SFPs) protect tumor cells against cytotoxic lymphocyte-mediated killing
Department of Cancer Research
The Student Training Project
Department of Cancer Research
Unraveling the genetic pathways underlying actin remodeling-mediated cancer immune evasion
Natural Killer cells and MAIT cells in chronic lung inflammation: effectors and/or exosome releasers?
Department of Infection and Immunity
Predictingthein vivoactivation potential of Th2 cells of patients
Department of Cancer Research
OVERCOMING TUMOR IMMUNE EVASION BY TARGETING THE ACTIN RESPONSE
Department of Cancer Research Translational Medicine Operations Hub (TMOH)
Prognostic Impact of Monocyte subsets in Patients with Glioblastoma
Department of Cancer Research
Shifting immune-suppressed monocyte-derived macrophage programs into microglia-like reactive cells in Glioblastoma
Department of Cancer Research
Harnessing DNA repair factors to promote an innate immune response against glioblastoma: an invitro RNAi screen selecting phagocytosis promoting genes in glioblastoma cells
Department of Cancer Research
Impact of MGMT on tumor development and resistance to temozolomide inglioblastoma: in vitro and in vivo characterization using novel GBM models
Department of Cancer Research
A NOVEL PERSONALIZED STRATEGY TARGETING DNA REPAIR PATHWAY ADDICTIONS IN GLIOBLASTOMA: FROM PATIENT STRATIFICATION TO PRECLINICAL VALIDATION
Department of Cancer Research
Roles of NEIL3 DNA glycosylase in telomere dynamics and DNA demethylation in glioblastoma: From molecular insights topreclinical target validation
Department of Cancer Research
Tumour microenvironment-induced invadopodia formation in cancer-associated fibroblasts: role in tumour cell invasion and metastasis
Department of Cancer Research
Training in Cancer Biology: Focus on Tumour Escape Mechanisms
Department of Cancer Research
Exosome proteins and RNA as biomarkers of prostate cancer progression and metastasis
Department of Cancer Research
Targeting DNA repair mechanisms in primary glioblastoma and their recurrences: from basic mechanisms to pre-clinical aspects and personalized therapy
Department of Cancer Research
Role of hypoxia in the establishment of an immune suppressive tumour microenvironment
Department of Infection and Immunity
The exosome proteome as a source of non-invasive biomarkers in solid tumours
Department of Cancer Research
Addressing the role of tumour associated microglia/macrophages in glioblastoma
Department of Cancer Research
CRP2, an innovative target to inhibit invadopodia activity and pro-metastatic MMP expression in breast cancer
Department of Cancer Research
National Centre of Translational Cancer Research
Department of Cancer Research
Improving cancer immunotherapy based on anti-PD-1 and STING agonists by combining small innovative molecule
Translational Medicine Operations Hub (TMOH) Department of Cancer Research
Personal Functional Profiling
Department of Cancer Research
4th Lecture Series in Cancer Research
Department of Cancer Research
3rd Lecture Series in Cancer Research
Department of Cancer Research Department of Infection and Immunity
Targeting chemokine receptors: An innovative strategy to reprogram cold to hot tumor microenvironment and to improve PD-1-based cancer immunotherapy
Department of Cancer Research
Impact of the immunomodulatory effect of the combination HDACis/IMiDs in myelome multiple (MM).
Department of Cancer Research
CD47 and PD-1 blockade: a new cutting edge COMBI approach to simultaneously stimulate macrophages and re-activate T cell-mediated destruction of highly aggressive metastatic breast tumors
Department of Cancer Research
Effect of PD-L1 blockade along with autophagy inhibition on the anti-tumor immune response
Department of Cancer Research
Combining selective pharmacological inhibitors of autophagy with NK immune checkpoint blockade anti-KIR: An innovative approach to improve NK-based cancer immunotherapy
Department of Cancer Research
Improving T-cell and Macrophage Immune checkpoint blockades by combining autophagy inhibitors
Department of Cancer Research
EMT-dependent regulation of the ectonucleotidase CD73 in Triple Negative Breast Cancer and its role as a new therapeutic target
Department of Cancer Research
Impact of the modulation of the intratumoral hypoxia on the improvement ofPD-1/PD-L1-based immune checkpoint blockade
Department of Cancer Research
IMPROVING CANCER IMMUNOTHERAPY BY TARGETING HYPOXIA
Department of Cancer Research
Combining JQI and PD-1 as an innovative approach for the treatment of Childhood Neuroblastoma.
Department of Cancer Research
Effect of PD-1/PD-L1 immune checkpoint blockade on NK cell-mediated anti-tumor immune response
Development of a novel combination therapy based on oncolytic parvovirus H-1PV and the BH3 mimetic ABT-737 against glioblastoma
Department of Cancer Research
Targeted delivery of theragnostic nanoparticles in glioblastoma
Department of Precision Health
Improving oral hormonal therapy adherence in breast cancer survivors – eHealth as a new intervention tool
Department of Precision Health
Assistance à partir de règles et de cas
Department of Precision Health Department of Infection and Immunity
Effects of pesticides on the gut and their role in cancer development
Department of Infection and Immunity
Therapeutic and Safety Evaluation of the CoMiX immunoconjugates as a novel complement activation-based immunotherapy strategy
Department of Infection and Immunity
From Systemic Lupus Erythematosus to Cancer: role of the Mutator Enzyme APOBEC3A in auto-immunity and tumorigenesis
Department of Infection and Immunity
Development of a personalised non-invasive diagnosis of endometrial cancer
Department of Infection and Immunity
Hif-α non-canonical regulation by PTMs and new interaction partners
Department of Infection and Immunity
Comprehensive analysis of the Hif1α interactome and its regulation by post-translational modifications
Department of Infection and Immunity
Spatio-temporal analysis of TGFβ receptor signalling and trafficking studied by peroxidase-mediated quantitative proximity proteomics and correlative imaging
Department of Precision Health
Effects of Chemotherapy-associated weight loss on pesticide burden and assessment of potential interference of pesticide exposure with the chemotherapy regimen
Decomposition of mixed transcriptomes for classification of heterogeneous tumour samples
Department of Cancer Research
Investigating the role of CMTM proteins in the regulation of PD-L1 expression
Department of Infection and Immunity
Study of the CXCL12-CXCR4/ACKR3 signaling in glioblastoma and of its importance in the control of translation and relapses
Department of Infection and Immunity Department of Cancer Research
Role of chemokine receptor-bearing extracellular vesicles in leukaemia and lymphoma
Department of Cancer Research
In Vivo Imaging Platform
Department of Cancer Research
MRgFUS facilitated local treatment of brain tumors
Department of Cancer Research
Assessment the impact of selective ALDH1 inhibitors on tumor infiltrating lymphocytes and the therapeutic benefit of Immune checkpoint blockers
Department of Cancer Research
CHECKPOINT INHIBITORS IMPROVEMENT FOR THE TREATMENT OF CANCER
Department of Cancer Research
Predictive biomarker profile for tumour and patient stratification for CyPep-1 guided ICI-therapy
Department of Cancer Research
Predictive and personalized medicine of pancreatic cancer
CAncer Registry Data available for cancer surveillance and monitoring
Department of Cancer Research
Personalized Functional Profiling – PFP
Clinical trials Recruiting
Department of Cancer Research
CANBIO2
Department of Cancer Research
High-content drug screening to inhibit actin cytoskeleton-mediated cancer immune evasion
Department of Infection and Immunity
Regulation of glioblastoma growth and tumor microenvironment by receptors ACKR3 and CXCR4
Department of Cancer Research
Targeting homologous recombination and replication stress in glioblastoma: from molecular insights to synthetic lethality approaches
Department of Cancer Research
DEVELOPMENT OF NEW TOOLS AND THERAPEUTICS FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
Department of Cancer Research
CYTOTOXIC CD4+ T CELLS AS NOVEL IMMUNOTHERAPY IN CLL AND OTHER B-CELL MALIGNANCIES
Department of Cancer Research
Role for the Itaconate/Nrf2 axis in metabolic and epigenetic reprogramming of neonatal macrophages
Department of Precision Health
Reducing Disparities in Cancer Outcomes
Department of Infection and Immunity
Epigenetic control of effector lymphocyte function
Department of Cancer Research
Targeting ALDH1L2 to enforce ER-stress sensitivity of cancer
Translational Medicine Operations Hub (TMOH) Department of Cancer Research
IPerGlio: Improving personalized glioblastoma care by intertwined immunomics and artificial intelligence approaches
Department of Cancer Research
Creation of National Comprehensive Cancer Centres and EU Networking
Translational Medicine Operations Hub (TMOH) Department of Cancer Research
PERSONAL FUNCTIONAL PROFILING FOR DRUG DISCOVERY IN MELANOMA AND COLORECTAL CANCER
Department of Cancer Research
Establishing of national cancer mission hubs and creation of network to support the mission on cancer
Department of Cancer Research
Prognostic impact of circulating monocyte subsets in glioblastoma patients
Department of Cancer Research
Overcoming treatment resistance with new therapeutic opportunities in leukaemia
Department of Cancer Research
Improving the Therapeutic benefit of immunotherapy in Neuroblastoma by combining autophagy inhibitor and anti-PD-i
Department of Cancer Research
Deconvolution of complex molecular signals of metabolomics and transcriptomics for predicting drug sensitivity and therapy resistance in malignant melanoma
Department of Precision Health
European Health Data & Evidence Network
Department of Precision Health
Colive Cancer
Department of Cancer Research
Investigating the mode of action of ACB1801 on increasing TAP1 and improving cancer immunotherapy
Department of Cancer Research
A Coordination and Support Action to prepare UNCAN.eu platform
Department of Precision Health
Monitoring mental health in breast cancer
Department of Cancer Research
Targeting Metastasis via its metabolic Achilles heel by exploiting BI-4916X and CompoundX
Department of Cancer Research
Role of ICAM-1 in mediating actin remodeling-dependent tumor immune evasion
Department of Cancer Research
Translation as Novel Therapeutic Target in CLL
Department of Cancer Research
NR1D2 circadian clock gene as a target for reverting glioblastoma associated-immunosuppression via functional modulation of myeloid cells.
Department of Cancer Research
Role of the transcription factors AHR and HIF-1alpha in the suppressive ability of regulatory T cells in chronic lymphocytic leukemia
Department of Cancer Research
Deciphering the role of the microbiome-derived oncometabolite formate on the immune cell compartment in colorectal cancer
Department of Cancer Research
Impact of intratumoral heterogeneity on treatment resistance and tumor relapse in glioblastoma
PNC Axe 3 Coordination
Translational Medicine Operations Hub (TMOH)
Data solutions based on a basket prospective trial with pembrolizumab and Vorinostat in patients with late stage squamous cell carcinoma
Department of Cancer Research
American Society of Hematology Global Research Award
Department of Cancer Research
Elucidating the role of the IRG1/ACOD1-itaconate axis in TAMs polarization in glioblastoma
Department of Infection and Immunity
Targeting the atypical chemokine receptor ACKR3 for improved cancer therapy
Department of Cancer Research
Role of hypoxia-induced autophagy in natural killer cell-mediated antitumor immune response
Department of Cancer Research
Targeting Intra-Tumor hypoxia and PD-L1 (TLV-2016)
Department of Infection and Immunity
Anti-Tumour Immunity: Tuning metabolic circuits in T-cells to fight cancer.
Department of Cancer Research
Anti-glycation drugs as immunotherapy
Department of Cancer Research
Improving the efficacy of renal cell carcinoma immunotherapy by combining anti-PD-1 and anti-CD47 immune checkpoints
Department of Cancer Research
Identification of new common predictive biomarkers to stratify TNBC breast cancer patients for treatment with emerging immune checkpoints
Department of Cancer Research
Harnessing DNA repair factors to promote an innate immune response against glioblastoma
Department of Cancer Research
Reciprocal effects of intrinsic tumour immune resistance and the tumour microenvironment
Department of Cancer Research Department of Infection and Immunity
Impact of the Adaptive Immunity on the Delayed Glioma Progression in a Mouse Model of Allergic Inflammation
Department of Cancer Research
Bioengineered small extracellular vesicles (sEV) as new cancer immunotherapies to counteract immune suppression
Department of Cancer Research
Immunometabolism adaptation in leukemia/lymphoma and new therapeutic opportunities
Department of Cancer Research
Strengthening research capacities of comprehensive cancer infrastructures
Department of Infection and Immunity
ldentification Of Clinically Relevant Compounds For The Enhancement Of Cd8 T Cell Metabolism And Function
Translational Medicine Operations Hub (TMOH)
CompOnco: Common targetable biomarkers in canine hemangiosarcoma and human angiosarcoma
Department of Infection and Immunity
CRISPR screens in primary human CD8 central memory T cells identify regulators driving CD8 TEMRA differentiation
Department of Cancer Research
Translation as novel therapeutic target in leukemia/lymphoma
Translational Medicine Operations Hub (TMOH)
Pre-operative methylation-based brain tumor classification
Department of Cancer Research
Delineating the role of caclium signaling in controlling formate overflow
Department of Cancer Research
Optimization of image acquisition protocols in Magnetic resonance Imaging (MRI) in oncology and neurology applications
Department of Cancer Research
Strengthening research capacities of comprehensive cancer infrastructures
Department of Cancer Research
Jury member for Doctoral thesis of Stefania Chounta, University Paris-Saclay
Department of Precision Health
RNC: National Cancer Registry
Department of Precision Health
CoLive Voice: Voice as Indicator of Health
Recruiting
Department of Cancer Research
Exosomes in B-cell malignancies
Department of Cancer Research
ACTIVASION project
Department of Cancer Research
Improving cancer immunotherapy based on anti-PD-1 and STING agonists by combining small innovative molecules (SMART-COMBO)
Department of Cancer Research
Elucidating tumour-associated microglia/macrophage heterogeneity for personalized immunotherapy in Glioblastoma
Department of Cancer Research
Glioma Longitudinal AnalySiS in Luxembourg: ex vivo and in vivo Functional Profiling of Recurrent Gliomas
Department of Cancer Research
The importance of being MitoFit: targeting mitochondrial metabolism in glioblastoma multiforme
Department of Infection and Immunity
Identifying Molecular Patterns of Atypical Chemokine Receptors for Translational Targeting
Department of Cancer Research
Identifying metabolic vulnerabilities in 3D
Department of Cancer Research
Tumour plasticity as a treatment resistance mechanism in glioblastoma.
Department of Cancer Research Department of Infection and Immunity
Personalized Medicine Acceleration through Rapid Omics Profiling
Department of Cancer Research
Formate-dependent Regulation of Cancer Metastasis
Translational Medicine Operations Hub (TMOH)
IMMUcan – Integrated IMMUnoprofiling of large adaptive CANcer patients cohorts
Translational Medicine Operations Hub (TMOH)
taRgeted thErapy for adVanced colorEctal canceR paTients
Department of Cancer Research
Understanding and targeting the function of formate overflow in cancer cells
Department of Precision Health
RELIANCE – Breast Cancer study
Department of Cancer Research
DNA repair mechanisms as molecular determinants of glioblastomachemoresistance: in vitro investigation and characterization of novel animalmodels
Department of Cancer Research
TARGETING TUMOR PROPAGATING CELLS IN GLIOBLASTOMA: FROM MECHANISTICINSIGHTS TO PRECISION MEDICINE
Department of Cancer Research
Targeting the glycolytic metabolism induced by anti-angiogenic treatment in Glioblastoma
Department of Cancer Research
Development of methodologies for monitoring cancer progression and predicting treatment response
Department of Cancer Research
Development of methodologies for monitoring cancer progression and predicting treatment response
Department of Cancer Research
Novel therapeutic agents to target escape mechanisms from anti-angiogenic treatment in Glioblastoma
Department of Cancer Research
Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics
Department of Cancer Research
Innovative Models and Oncolytic Viruses for Immunotherapy of Glioblastoma
Department of Cancer Research
ImmoGBM
Department of Cancer Research
Targeting Glioma Cell Invasion
Department of Cancer Research
Implication of LncRNAs in chemoresistance in Glioblastom
Department of Cancer Research
LRIG1: an Endogenous Inhibitor for Pan-Receptor Tyrosine Kinase Targeting in Glioblastoma
Department of Cancer Research
A multi-omics based single-cell strategy to overcome therapy-driven resistance in Glioblastoma: An entry-point for personalized treatment
Department of Cancer Research
Targeted Epigenetic Therapy for Relapsed Glioblastoma
Department of Cancer Research
Moving innovative oncolytic virus-based therapies into the clinic
Department of Cancer Research
Development of novel oncolytic Paroviruses with ability to silence the TRAF3IP2 Gene as novel therapeutics against Glioblastoma
Department of Infection and Immunity Department of Cancer Research
MS-based proteomic approach to characterize phosphosignaling in glioblastoma
Department of Cancer Research
Training of next generation of European glioblastoma (translational) researchers, to resolve precision targeting of the brain tumour microenvironment
Department of Cancer Research
IMPACT OF EPITRANSCRIPTOMIC REGULATION ON RESPONSE TO PHARMACOLOGICAL TREATMENTS IN GLIOMAS
Department of Cancer Research
Pseudo PET imaging of brain tumor hypoxia
Department of Cancer Research
Roles of the epigenetic reader MBD1 in IDH1-mutated gliomas
Department of Cancer Research
Chemoresistance-related RNAs in GBM
Department of Cancer Research
Impact of IDH1 mutation on Epitranscriptome regulation in Gliomas
Department of Cancer Research
INVOLVEMENT OF LONG NON-CODING RNA MECHANISMS IN GLIOBLASTOMA
Department of Cancer Research
In search of RNA Therapeutic Drugs in Oncology
Department of Cancer Research
Reverting Cancer Driver Mutations in Gliomas
Department of Cancer Research
TACKLING TUMOR HETEROGENEITY AND PLASTICITY AS RESISTANCE MECHANISMS IN GLIOBLASTOMA
Department of Cancer Research
Targeting tumor propagating cells in glioblastoma: from mechanistic insights to precision medicine
Department of Cancer Research
The role of mitochondrial folate metabolism during macrophage polarization (Mac1L)
Department of Infection and Immunity Department of Cancer Research
SMART GLIOBLASTOMA: Signaling and Modulation of the AtypicalIsoform of the CXCR3 RecepTor in glioblastoma cells
Department of Precision Health
Registre National du Cancer – National Cancer Regestry
Department of Cancer Research
Deconvolution of heterogeneity in the Glioblastoma cellular ecosystem for understanding treatment resistance and improving patient stratification
Department of Cancer Research
Glioma Longitudinal AnalySiS in Luxembourg (GLASS-LUX): ex vivo and in vivo Functional Profiling of Recurrent Gliomas
Department of Precision Health
REaL-life cANCEr epidemiology Publication of cancer registry data for cancer control & prevention
Department of Cancer Research
5th Lecture Series in Cancer Research
Department of Cancer Research
Precision medicine for Glioblastoma patients: a patient-based pre-clinical platform for immuno-oncology

Related News

All news